Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947890 | 0.89 | MEN1 (1.00) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL29424354 | 0.81 | MEN1 (0.69) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL17225124 | 0.80 | MEN1 (0.52) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL13039178 | 0.72 | KMT2A (0.71) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL1948599 | 0.72 | KMT2A (0.71) | MEN1KMT2AALOX15CA1CA2 | |
| SCHEMBL3449990 | 0.71 | CA12 (0.55) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL7045570 | 0.70 | CA1 (0.63) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL10592552 | 0.70 | CA12 (0.53) | MEN1KMT2AALOX15CA12CA1 | |
| SCHEMBL10665928 | 0.69 | LMNA (0.64) | KMT2ACA12CA1CA2CA3 | |
| SCHEMBL1925919 | 0.69 | L3MBTL1 (0.48) | MEN1KMT2AALOX15CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | MEN1 2808/4885KMT2A 2680/4885ALOX15 2398/4885 |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | TYMP, PAICS, ENTPD5 | MEN1 2040/4885KMT2A 2252/4885ALOX15 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.